Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy

Multiple sclerosis is a chronic autoimmune disease of the central nervous system. Multiple sclerosis causes demyelination, impaired nervous system function, and eventually neurodegeneration. Microglia are cells of the central nervous system that develop from yolk sac macrophages during embryogenesi...

Full description

Saved in:
Bibliographic Details
Main Authors: P. Valiukevičius, R. Liutkevičienė, R. Balnytė
Format: Article
Language:English
Published: Vilnius University Press 2023-10-01
Series:Neurologijos seminarai
Subjects:
Online Access:https://www.journals.vu.lt/neurologijos_seminarai/article/view/33262
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832593108375699456
author P. Valiukevičius
R. Liutkevičienė
R. Balnytė
author_facet P. Valiukevičius
R. Liutkevičienė
R. Balnytė
author_sort P. Valiukevičius
collection DOAJ
description Multiple sclerosis is a chronic autoimmune disease of the central nervous system. Multiple sclerosis causes demyelination, impaired nervous system function, and eventually neurodegeneration. Microglia are cells of the central nervous system that develop from yolk sac macrophages during embryogenesis. These cells perform important functions in the development of the central nervous system and the retina, in the formation of synapses, protect against pathogens, and are involved in the removal of damaged structures. In response to environmental factors, microglia can acquire an inflammatory or anti-inflammatory phenotype. Microglia also play an important role in the pathogenesis of multiple sclerosis, and these cells are thought to be involved in both demyelination and remyelination processes. Microglial cells phagocytose harmful myelin remnants, promote remyelination, and control the proper response of peripheral immune cells, but disruption of these functions can lead to demyelination and neurodegeneration. Many of the disease-modifying drugs used to treat multiple sclerosis also affect microglial cells and inhibit their inflammatory response. Currently, new drugs are being researched that could be used to treat multiple sclerosis promoting the transition of microglia to an anti-inflammatory phenotype. The latest advanced cell therapy drugs have a broader spectrum of action – they inhibit inflammation, promote angiogenesis, perform trophic function, and inhibit oxidative damage.
format Article
id doaj-art-5283e92f7f9c4ccf8f064a3460fc8d13
institution Kabale University
issn 1392-3064
2424-5917
language English
publishDate 2023-10-01
publisher Vilnius University Press
record_format Article
series Neurologijos seminarai
spelling doaj-art-5283e92f7f9c4ccf8f064a3460fc8d132025-01-20T18:22:11ZengVilnius University PressNeurologijos seminarai1392-30642424-59172023-10-01263 (93)10.29014/NS.2022.26.14Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapyP. Valiukevičius0R. Liutkevičienė1R. Balnytė2Lithuanian University of Health SciencesLithuanian University of Health SciencesLithuanian University of Health Sciences Multiple sclerosis is a chronic autoimmune disease of the central nervous system. Multiple sclerosis causes demyelination, impaired nervous system function, and eventually neurodegeneration. Microglia are cells of the central nervous system that develop from yolk sac macrophages during embryogenesis. These cells perform important functions in the development of the central nervous system and the retina, in the formation of synapses, protect against pathogens, and are involved in the removal of damaged structures. In response to environmental factors, microglia can acquire an inflammatory or anti-inflammatory phenotype. Microglia also play an important role in the pathogenesis of multiple sclerosis, and these cells are thought to be involved in both demyelination and remyelination processes. Microglial cells phagocytose harmful myelin remnants, promote remyelination, and control the proper response of peripheral immune cells, but disruption of these functions can lead to demyelination and neurodegeneration. Many of the disease-modifying drugs used to treat multiple sclerosis also affect microglial cells and inhibit their inflammatory response. Currently, new drugs are being researched that could be used to treat multiple sclerosis promoting the transition of microglia to an anti-inflammatory phenotype. The latest advanced cell therapy drugs have a broader spectrum of action – they inhibit inflammation, promote angiogenesis, perform trophic function, and inhibit oxidative damage. https://www.journals.vu.lt/neurologijos_seminarai/article/view/33262microgliamultiple sclerosispathogenesisadvanced therapy medicinal products
spellingShingle P. Valiukevičius
R. Liutkevičienė
R. Balnytė
Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
Neurologijos seminarai
microglia
multiple sclerosis
pathogenesis
advanced therapy medicinal products
title Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
title_full Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
title_fullStr Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
title_full_unstemmed Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
title_short Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
title_sort role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
topic microglia
multiple sclerosis
pathogenesis
advanced therapy medicinal products
url https://www.journals.vu.lt/neurologijos_seminarai/article/view/33262
work_keys_str_mv AT pvaliukevicius roleofmicrogliainthepathogenesisofmultiplesclerosisandlinkstoimmunomodulatorytherapy
AT rliutkeviciene roleofmicrogliainthepathogenesisofmultiplesclerosisandlinkstoimmunomodulatorytherapy
AT rbalnyte roleofmicrogliainthepathogenesisofmultiplesclerosisandlinkstoimmunomodulatorytherapy